Interleukin Genetics reported increased revenues for its fiscal fourth quarter of 2015 but also an increase in net loss, compared with the same quarter the previous year.
For the quarter (end-December 31), the company reported revenues of $366,000, compared with $322,000 for the same quarter of 2014. Net loss for the quarter was $1.9 million, compared with $1.6 million in 2014.
For the full-year 2015 results, the company reported revenues of $1.44 million, compared with $1.81 million for the previous year. Net loss for 2015 was $7.9 million, compared with a net loss of $6.3 million for 2014. The company attributed the increase in revenue loss largely to a decrease in the number of returned kits for processing.
"2015 was an important year for Interleukin Genetics, as we focused on developing and executing a significantly updated strategic and operational plan centered on the medical value of our genetic test, PerioPredict," stated Mark Carbeau, CEO of Interleukin Genetics, in a press release.
